Targeted literature review of the burden of extraintestinal pathogenic Escherichia Coli among elderly patients in Asia Pacific regions-Reference-Cited by-同舟云学术

Targeted literature review of the burden of extraintestinal pathogenic Escherichia Coli among elderly patients in Asia Pacific regions

Published:2023-02 Issue:1 Volume:26 Page:168-178
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Ohmagari Norio¹,Choi Won Suk²,Tang Hung-Jen³,Atanasov Petar⁴,Jiang Xiaobin⁵,Hernandez Pastor Luis⁶,Nakayama Yoshikazu⁷^ORCID,Chiang Jason⁷,Lim Kyunghwa⁸,Nievera Maria Carmen⁹^ORCID

Affiliation:

1. National Center for Global Health and Medicine, Tokyo, Japan

2. Korea University Ansan Hospital, Ansan, South Korea

3. ChiMei Medical Center, Tainan, Taiwan

4. Health Economics and Market Access, Amaris Consulting, Barcelona, Spain

5. Health Economics and Market Access, Amaris Consulting, Shanghai, China

6. Janssen Pharmaceutica NV, Beerse, Belgium

7. Janssen Pharmaceuticals, Tokyo, Japan

8. Janssen Asia Pacific, Seoul, South Korea

9. Janssen Pharmaceuticals, Metro Manila, Philippines

Funder

Janssen Asia Pacific

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2169447

Reference52 articles.

1. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem

2. Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages

3. Extraintestinal PathogenicEscherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field

4. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

5. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60 to 85 years in a randomized, double-blind, phase 1 study.;Journal of Infection and Chemotherapy;2024-09

2. A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease;Journal of Antimicrobial Chemotherapy;2024-07-13

3. Progress toward a vaccine for extraintestinal pathogenic E. coli (ExPEC) II: efficacy of a toxin-autotransporter dual antigen approach;Infection and Immunity;2024-05-07

4. Impact of Invasive Escherichia Coli Disease on Clinical Outcomes and Medical Resource Utilization Among Asian Patients in the United States;Infectious Diseases and Therapy;2024-01-24

5. Trends in Antibiotic Resistance Patterns and Burden of Escherichia Coli Infections in Young Children: A Retrospective Cross-Sectional Study in Shenzhen, China from 2014–2018;Infection and Drug Resistance;2023-08